

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 14, 2025

PE-Cy™7 Hamster Anti-Mouse CD95

RRID:AB_396768

Type: Antibody

Proper Citation

(BD Biosciences Cat# 557653, RRID:AB_396768)

Antibody Information

URL: http://antibodyregistry.org/AB_396768

Proper Citation: (BD Biosciences Cat# 557653, RRID:AB_396768)

Target Antigen: CD95

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: PE-Cy™7 Hamster Anti-Mouse CD95

Description: This monoclonal targets CD95

Target Organism: mouse

Clone ID: [Jo2]

Antibody ID: AB_396768

Vendor: BD Biosciences

Catalog Number: 557653

Record Creation Time: 20241016T221716+0000

Record Last Update: 20241016T223443+0000

Ratings and Alerts

No rating or validation information has been found for PE-Cy™7 Hamster Anti-Mouse CD95.

No alerts have been found for PE-Cy™7 Hamster Anti-Mouse CD95.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 90 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Schiepers A, et al. (2024) Opposing effects of pre-existing antibody and memory T cell help on the dynamics of recall germinal centers. *Immunity*, 57(7), 1618.

Hernández-Barranco A, et al. (2024) NGFR regulates stromal cell activation in germinal centers. *Cell reports*, 43(2), 113705.

Wu M, et al. (2024) Innervation of nociceptor neurons in the spleen promotes germinal center responses and humoral immunity. *Cell*, 187(12), 2935.

Jiang W, et al. (2024) Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization. *Cell reports*, 43(1), 113665.

Bierling TEH, et al. (2024) GLUT1-mediated glucose import in B cells is critical for anaplerotic balance and humoral immunity. *Cell reports*, 43(2), 113739.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. *Cancer cell*.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. *Cancer cell*.

Ray R, et al. (2024) Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses. *Immunity*, 57(5), 1141.

Xu T, et al. (2024) Notch2 signaling governs activated B cells to form memory B cells. *Cell reports*, 43(7), 114454.

Mayberry CL, et al. (2024) Protocol to assess bioenergetics and mitochondrial fuel usage in murine autoreactive immunocytes using the Seahorse Extracellular Flux Analyzer. *STAR protocols*, 5(2), 102971.

Cooper L, et al. (2024) Type I interferons induce an epigenetically distinct memory B cell subset in chronic viral infection. *Immunity*, 57(5), 1037.

Li X, et al. (2024) Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation. *Immunity*, 57(7), 1603.

Dvorscek AR, et al. (2024) Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity. *Immunity*, 57(10), 2433.

Chege Kuria T, et al. (2024) In vivo analysis of CRISPR-edited germinal center murine B cells. *Frontiers in immunology*, 15, 1473760.

Bolonsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Fike AJ, et al. (2023) STAT3 signaling in B cells controls germinal center zone organization and recycling. *Cell reports*, 42(5), 112512.

Chen ST, et al. (2023) B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection. *Immunity*, 56(3), 547.

Li J, et al. (2023) Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas. *bioRxiv : the preprint server for biology*.

Wilson JJ, et al. (2023) Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment. *iScience*, 26(9), 107487.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.